Amarantus Bioscience Holdings Inc (AMBS)

[jason_luke]

Load the boat! News this month. Mallinckrodt just bought Strattech Corp. this month for Stratagraft, which is in development for treatment of severe burns. Stratagraft, much like ESS, is a regenerative living tissue designed to mimic key attributes of human skin and reduce the need for painful autograft. Both Stratagraft and ESS contain dermal and epidermal skin layers.

http://stratatechcorp.com/news/MNK%20Acquisition.pdf

AMBS, with MC of $3 million and trades for 5 cents, has a Letter of Intent (the "LOI”)? with a commercial-stage wound-care company to form a joint venture (the "JV") for the further development of the ESS program. The exclusivity period of the LOI, has been extended for an additional 30 days to August 29th, 2016. MONDAY FOLKS.

http://ir.amarantus.com/all-sec-filings#document-24652-0001213900-16-015585

AMBS just reported fantastic data this month on ESS. Publication of the recent article, "Randomized, Paired-Site Comparison of Autologous Engineered Skin Substitutes and Split-Thickness Skin Graft for Closure of Extensive, Full-Thickness Burns" showed extremely impressive results. ESS has improved upon Apligraf by incorporating autologous keratinocytes and fibroblasts from the patient into their scaffold. Data from this study show that
autologous ESSs reduce harvesting of donor skin in
pediatric patients for closure of burn injuries involving
greater than 50% TBSA. This would presumably apply to adult patients as well. Decreased donor skin requirements means less donor site morbidity, fewer skin-grafting operations, and fewer days in intensive care.